[Clinical experience with NK 631 in malignant tumors of skin (author's transl)].
NK 631, a new derivative of bleomycin, was clinically used in 14 cases of malignant tumors of skin. The results obtained were remarkably effective in 7 cases, effective in 3 cases, slightly effective in 2 cases and ineffective in 2 cases. The effective ratio was 71% when calculated regarding slightly effective as ineffective. Compared with bleomycin, we were impressed that the side effects observed with NK 631 were similar to those with bleomycin, but the influences for lung were smaller and slighter than the latter.
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
D001761:Bleomycin